Notable Downgrades: Energy Corp. (BTU), Electronic Arts (EA), AcelRx Pharmaceuticals (ACRX), Ziopharm (ZIOP)

Analysts at Jefferies downgraded Peabody Energy Corp. (BTU) from ‘Buy‘ to ‘Hold‘ in a research report issued to clients on Tuesday.

The t-12-month revenue at Peabody Energy Corp. is $6.73 billion. BTU ‘s ROE for the same period is (22.45%).

Shares of the $1.68 billion market cap company are down 61.23% year-over-year and 17.96% year-to-date. BTU, currently with a median Wall Street price target of $10.00 and a high target of $15.00, dropped $0.23 to $6.12 in recent trading.

The chart below shows where the equity has traded over the past 52-weeks.

Electronic Arts Inc. (EA) was downgraded from ‘Buy‘ to ‘Hold‘ at Needham.

Shares have traded today between $54.51 and $55.84 with the price of the stock fluctuating between $26.64 to $58.87 over the last 52 weeks.

Electronic Arts Inc. shares are currently changing hands at 21.40x this year’s forecasted earnings, compared to the industry’s 16.07x earnings multiple. Ticker has a t-12 price/sales ratio of 3.95. EPS for the same period registers at $2.59.

Shares of EA have lost $1.17 to $55.49 in mid-day trading on Tuesday, giving it a market cap of roughly $17.20 billion. The stock traded as high as $58.87 in Feb. 26, 2015.

Jefferies reported on Tuesday that they have lowered their rating for AcelRx Pharmaceuticals, Inc. (ACRX). The firm has downgraded ACRX from ‘Buy‘ to ‘Hold‘.

AcelRx Pharmaceuticals Inc. recently traded at $4.94, a loss of $0.57 over Monday’s closing price. The name has a current market capitalization of $215.91 million.

Ziopharm Oncology, Inc. (ZIOP) had its rating lowered from ‘Buy‘ to ‘Neutral‘ by analysts at Mizuho on Tuesday. The firm sees shares as fairly valued at $14, versus $13.91 close. Currently there are 3 analysts that rate ZIOP a ‘Buy’, no analyst rates it a ‘Sell’, and 1 rates it a ‘Hold’.

ZIOP was down $0.39 at $13.52 in mid-day trade, moving within a 52-week range of $2.31 to $14.27. The name, valued at $1.41 billion, opened at $13.19.

On valuation measures, Ziopharm Oncology Inc. shares have a t-12 price/sales ratio of 1,056. EPS for the same period registers at ($0.31).

Be the first to comment

Leave a Reply

Your email address will not be published.


*